Goettingen, Germany — Jul 14^th, 2010: DeveloGen AG, a company focused on the discovery and development of therapies for the treatment of diabetes and other metabolic diseases, announced today that Evotec AG, Hamburg (Deutsche Börse: EVT, Tec DAX), has entered into a definitive agreement with a group of shareholders of DeveloGen AG to acquire a majority shareholding in the company. Dr. Cord Dohrmann, current CEO of DeveloGen AG, will become CSO of Evotec.

Through the acquisition, Evotec gains access to DeveloGen’s metabolic disease technology, know-how and expertise including two highly innovative diabetes projects partnered with Boehringer Ingelheim and Andromeda Biotech as well as the company’s beta cell regeneration program. DeveloGen’s contract research service business, which provides a broad range of in vitro and in vivo pharmacology services, complements the acquired assets.

"By gaining access to Evotec’s world class small molecule drug discovery platform, DeveloGen will significantly increase its ability to expand on its drug discovery efforts in the area of metabolic disease," says Carsten Dehning, CFO of DeveloGen AG.

"DeveloGen brings to Evotec a highly complementary technology platform, know-how and expertise. The company also comes with existing and potential future discovery alliances with renowned pharmaceutical companies in the area of metabolic disease," adds Dr. Helmut Schühsler, Managing Partner of TVM Capital and Chairman of the Supervisory Board of DeveloGen AG. "We strongly believe the business combination is a great fit for both companies. The long term value of the combined business will be based on a comprehensive integrated platform of biology and chemistry know-how and capabilities in a selected number of medical indications."

Under the terms of the agreement, Evotec will acquire in excess of 99% of the outstanding shares in DeveloGen AG. The majority of the consideration is to be paid in Evotec shares with the remainder in cash and performance related deferred payments. Following the transaction, Evotec intends to offer a cash compensation for the acquisition of the remaining shares of DeveloGen AG.

Cord Dohrmann, current CEO of DeveloGen AG will become CSO of Evotec to provide scientific vision and strategy in line with the group’s goal to aggressively grow its drug discovery alliances business through the addition of disease know-how in key indications and cutting edge drug discovery technology.

About DeveloGen AG

DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine diseases. The Company has a highly innovative and deep preclinical discovery pipeline addressing the key drivers in the development of diabetes and obesity such as insulin resistance and loss of insulin-producing beta cells. This pipeline includes programs for the potential treatment of obesity through orally available small molecules based on novel and proprietary targets as well as growth factors targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Göttingen, Germany. For more information on DeveloGen, please visit www.develogen.com.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com.

Contact:

DeveloGen AG Carsten Dehning Chief Financial Officer Marie-Curie-Str. 7 37079 Goettingen, Germany Tel: +49 551 50558 514 dehning@develogen.com